• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

1.400 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.400
Bid (Size) 0.5600 (200)
Ask (Size) 1.550 (900)
Prev. Close 1.400
Today's Range 1.400 - 1.400
52wk Range 0.6100 - 5.480
Shares Outstanding 23,541,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ABVC BioPharma Provides Corporate and Structural Update
February 24, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Provides Corporate and Structural Update
February 24, 2026
SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company focused on botanical-derived... 
Via TheNewswire.com
Topics Intellectual Property

Performance

YTD
-36.1%
-36.1%
1 Month
-32.4%
-32.4%
3 Month
-45.5%
-45.5%
6 Month
-53.0%
-53.0%
1 Year
+88.8%
+88.8%

More News

Read More
News headline image
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
December 02, 2025
Via NewMediaWire
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
December 02, 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
November 26, 2025
Via NewMediaWire
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
November 26, 2025
Via TheNewswire.com
News headline image
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
November 21, 2025
Via NewMediaWire
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
November 21, 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
November 18, 2025
Via NewMediaWire
Topics Artificial Intelligence
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
November 18, 2025
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
November 03, 2025
Via NewMediaWire
News headline image
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
November 03, 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
October 31, 2025
Via NewMediaWire
News headline image
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
October 31, 2025
Via TheNewswire.com
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
October 17, 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
October 17, 2025
Via NewMediaWire
News headline image
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
October 08, 2025
Via NewMediaWire
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
October 08, 2025
Via TheNewswire.com
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
September 19, 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
September 19, 2025
Via NewMediaWire
News headline image
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
August 29, 2025
Via NewMediaWire
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
August 29, 2025
Via TheNewswire.com
News headline image
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
August 27, 2025
Via NewMediaWire
News headline image
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
August 27, 2025
Via TheNewswire.com
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
August 22, 2025
Via TheNewswire.com

Frequently Asked Questions

Is ABVC BioPharma, Inc. - Common Stock publicly traded?
Yes, ABVC BioPharma, Inc. - Common Stock is publicly traded.
What exchange does ABVC BioPharma, Inc. - Common Stock trade on?
ABVC BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ABVC BioPharma, Inc. - Common Stock?
The ticker symbol for ABVC BioPharma, Inc. - Common Stock is ABVC on the Nasdaq Stock Market
What is the current price of ABVC BioPharma, Inc. - Common Stock?
The current price of ABVC BioPharma, Inc. - Common Stock is 1.400
When was ABVC BioPharma, Inc. - Common Stock last traded?
The last trade of ABVC BioPharma, Inc. - Common Stock was at 02/24/26 04:00 PM ET
What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?
The market capitalization of ABVC BioPharma, Inc. - Common Stock is 32.96M
How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?
ABVC BioPharma, Inc. - Common Stock has 33M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap